Literature DB >> 21290151

Biopterin levels in the cerebrospinal fluid of patients with PARK8 (I2020T).

Shoko Koshiba1, Hirofumi Tokuoka, Teruo Yokoyama, Emiko Horiuchi, Hiroshi Ichinose, Kazuko Hasegawa.   

Abstract

PARK8 is the most common form of familial Parkinson's disease (PD). We measured biopterin and monoamine metabolite levels in the cerebrospinal fluids of 7 PARK8 patients (I2020T mutation in leucine-rich repeat kinase 2), 2 asymptomatic mutation carriers, and 21 sporadic PD patients. The biopterin levels in PARK8 patients were significantly higher than those in sporadic PD patients, although the symptoms were comparable in both groups, suggesting that PARK8 patients exhibit parkinsonian symptoms with higher biopterin levels than sporadic PD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21290151     DOI: 10.1007/s00702-011-0587-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  20 in total

1.  Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease.

Authors:  Satoshi Orimo; Takeshi Amino; Yoshinori Itoh; Atsushi Takahashi; Tohru Kojo; Toshiki Uchihara; Kuniaki Tsuchiya; Fumiaki Mori; Koichi Wakabayashi; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2005-06-03       Impact factor: 17.088

2.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.

Authors:  Kazuko Hasegawa; A Jon Stoessl; Teruo Yokoyama; Hisayuki Kowa; Zbigniew K Wszolek; Saburo Yagishita
Journal:  Parkinsonism Relat Disord       Date:  2008-09-18       Impact factor: 4.891

3.  Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.

Authors:  F C Cheng; J S Kuo; L G Chia; G Dryhurst
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Authors:  John R Adams; Hinke van Netten; Michael Schulzer; Edwin Mak; Jessamyn Mckenzie; Audrey Strongosky; Vesna Sossi; Thomas J Ruth; Chong S Lee; Matthew Farrer; Thomas Gasser; Ryan J Uitti; Donald B Calne; Zbigniew K Wszolek; A Jon Stoessl
Journal:  Brain       Date:  2005-08-04       Impact factor: 13.501

5.  Analysis of reduced forms of biopterin in biological tissues and fluids.

Authors:  T Fukushima; J C Nixon
Journal:  Anal Biochem       Date:  1980-02       Impact factor: 3.365

6.  Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Authors:  H L Melrose; J C Dächsel; B Behrouz; S J Lincoln; M Yue; K M Hinkle; C B Kent; E Korvatska; J P Taylor; L Witten; Y-Q Liang; J E Beevers; M Boules; B N Dugger; V A Serna; A Gaukhman; X Yu; M Castanedes-Casey; A T Braithwaite; S Ogholikhan; N Yu; D Bass; G Tyndall; G D Schellenberg; D W Dickson; C Janus; M J Farrer
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

7.  (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

Authors:  S Orimo; E Ozawa; S Nakade; T Sugimoto; H Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

8.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

9.  Significance of CSF total neopterin and biopterin in inflammatory neurological diseases.

Authors:  Y Furukawa; K Nishi; T Kondo; K Tanabe; Y Mizuno
Journal:  J Neurol Sci       Date:  1992-08       Impact factor: 3.181

10.  Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Authors:  Yanping Li; Wencheng Liu; Tinmarla F Oo; Lei Wang; Yi Tang; Vernice Jackson-Lewis; Chun Zhou; Kindiya Geghman; Mikhail Bogdanov; Serge Przedborski; M Flint Beal; Robert E Burke; Chenjian Li
Journal:  Nat Neurosci       Date:  2009-06-07       Impact factor: 24.884

View more
  3 in total

1.  Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.

Authors:  Hiroshi Ichinose; Ken-Ichi Inoue; Shinobu Arakawa; Yuki Watanabe; Hiroki Kurosaki; Shoko Koshiba; Eldbjorg Hustad; Masahiko Takada; Jan O Aasly
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

Review 2.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

Review 3.  What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?

Authors:  David A Loeffler; Jan O Aasly; Peter A LeWitt; Mary P Coffey
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.